JPH06505253A - Ｅｌａｍ−１に対するモノクロナール抗体及びそれらの使用 - Google Patents

Ｅｌａｍ−１に対するモノクロナール抗体及びそれらの使用

Info

Publication number: JPH06505253A
Authority: JP; Japan
Prior art keywords: elam; cells; immunoglobulin; antibodies; antibody
Prior art date: 1991-01-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP4505427A

Other languages

English (en)

Japanese (ja)

Inventor

ウェイナー，エリザベス

フィリップス，メアリー　エル．

ウィンケルヘイク，ジェフリー　エル．

Original Assignee

サイテル　コーポレイション

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-24

Filing date

1992-01-23

Publication date

1994-06-16

1992-01-23 Application filed by サイテル　コーポレイション filed Critical サイテル　コーポレイション

1994-06-16 Publication of JPH06505253A publication Critical patent/JPH06505253A/ja

Status Pending legal-status Critical Current

Links

108010024212 E-Selectin Proteins 0.000 title claims description 36
102000015689 E-Selectin Human genes 0.000 title claims description 10
238000000034 method Methods 0.000 claims description 73
210000004027 cell Anatomy 0.000 claims description 72
108060003951 Immunoglobulin Proteins 0.000 claims description 41
102000018358 immunoglobulin Human genes 0.000 claims description 41
229940072221 immunoglobulins Drugs 0.000 claims description 18
230000001404 mediated effect Effects 0.000 claims description 17
230000037396 body weight Effects 0.000 claims description 12
238000006243 chemical reaction Methods 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 10
230000004044 response Effects 0.000 claims description 9
230000006378 damage Effects 0.000 claims description 8
230000001575 pathological effect Effects 0.000 claims description 8
206010061218 Inflammation Diseases 0.000 claims description 6
230000004054 inflammatory process Effects 0.000 claims description 6
230000028709 inflammatory response Effects 0.000 claims description 6
230000005732 intercellular adhesion Effects 0.000 claims description 6
206010040070 Septic Shock Diseases 0.000 claims description 5
208000027418 Wounds and injury Diseases 0.000 claims description 5
239000002246 antineoplastic agent Substances 0.000 claims description 5
208000014674 injury Diseases 0.000 claims description 5
230000036303 septic shock Effects 0.000 claims description 5
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
206010040047 Sepsis Diseases 0.000 claims description 4
229940127089 cytotoxic agent Drugs 0.000 claims description 4
206010027476 Metastases Diseases 0.000 claims description 3
230000003110 anti-inflammatory effect Effects 0.000 claims description 3
210000000987 immune system Anatomy 0.000 claims description 3
230000009401 metastasis Effects 0.000 claims description 3
230000017455 cell-cell adhesion Effects 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 2
210000003705 ribosome Anatomy 0.000 claims 1
239000002502 liposome Substances 0.000 description 31
239000002158 endotoxin Substances 0.000 description 27
102100023471 E-selectin Human genes 0.000 description 26
238000003556 assay Methods 0.000 description 26
239000000203 mixture Substances 0.000 description 24
210000002889 endothelial cell Anatomy 0.000 description 20
238000011282 treatment Methods 0.000 description 20
210000000440 neutrophil Anatomy 0.000 description 19
108090000623 proteins and genes Proteins 0.000 description 19
210000003622 mature neutrocyte Anatomy 0.000 description 18
239000002609 medium Substances 0.000 description 17
241000700159 Rattus Species 0.000 description 16
210000001772 blood platelet Anatomy 0.000 description 16
239000000725 suspension Substances 0.000 description 16
241001465754 Metazoa Species 0.000 description 14
108090000184 Selectins Proteins 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
239000003814 drug Substances 0.000 description 14
230000000694 effects Effects 0.000 description 14
239000000243 solution Substances 0.000 description 14
102000003800 Selectins Human genes 0.000 description 13
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
229940079593 drug Drugs 0.000 description 13
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
239000011780 sodium chloride Substances 0.000 description 12
210000000265 leukocyte Anatomy 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
108010035766 P-Selectin Proteins 0.000 description 9
102100023472 P-selectin Human genes 0.000 description 9
239000002253 acid Substances 0.000 description 9
239000000872 buffer Substances 0.000 description 9
210000003038 endothelium Anatomy 0.000 description 9
230000007246 mechanism Effects 0.000 description 9
108091028043 Nucleic acid sequence Proteins 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
230000000295 complement effect Effects 0.000 description 8
239000012634 fragment Substances 0.000 description 8
239000007924 injection Substances 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000003446 ligand Substances 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
239000012528 membrane Substances 0.000 description 8
210000004379 membrane Anatomy 0.000 description 8
239000000126 substance Substances 0.000 description 8
230000008685 targeting Effects 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
108020004414 DNA Proteins 0.000 description 7
210000004204 blood vessel Anatomy 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
238000001990 intravenous administration Methods 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
239000000427 antigen Substances 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
229940098773 bovine serum albumin Drugs 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
208000027866 inflammatory disease Diseases 0.000 description 6
239000007788 liquid Substances 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
239000011537 solubilization buffer Substances 0.000 description 6
238000012546 transfer Methods 0.000 description 6
OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 5
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
239000008273 gelatin Substances 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
238000002156 mixing Methods 0.000 description 5
210000003281 pleural cavity Anatomy 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
238000012360 testing method Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
239000013598 vector Substances 0.000 description 5
241000282412 Homo Species 0.000 description 4
108700005091 Immunoglobulin Genes Proteins 0.000 description 4
108010092694 L-Selectin Proteins 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
238000007792 addition Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000007979 citrate buffer Substances 0.000 description 4
238000010367 cloning Methods 0.000 description 4
239000012636 effector Substances 0.000 description 4
210000003714 granulocyte Anatomy 0.000 description 4
239000010410 layer Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 4
238000000746 purification Methods 0.000 description 4
238000012216 screening Methods 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
229910052717 sulfur Inorganic materials 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
101800003838 Epidermal growth factor Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
241000272184 Falconiformes Species 0.000 description 3
102000006395 Globulins Human genes 0.000 description 3
108010044091 Globulins Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
102000016551 L-selectin Human genes 0.000 description 3
241001529936 Murinae Species 0.000 description 3
102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000034994 death Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000009826 distribution Methods 0.000 description 3
229940116977 epidermal growth factor Drugs 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000004968 inflammatory condition Effects 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
210000004224 pleura Anatomy 0.000 description 3
208000008423 pleurisy Diseases 0.000 description 3
230000008569 process Effects 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
210000003556 vascular endothelial cell Anatomy 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
102000029816 Collagenase Human genes 0.000 description 2
108060005980 Collagenase Proteins 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
108010087819 Fc receptors Proteins 0.000 description 2
102000009109 Fc receptors Human genes 0.000 description 2
-1 For example Chemical class 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
102000012750 Membrane Glycoproteins Human genes 0.000 description 2
108010090054 Membrane Glycoproteins Proteins 0.000 description 2
102000005717 Myeloma Proteins Human genes 0.000 description 2
108010045503 Myeloma Proteins Proteins 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
108010003541 Platelet Activating Factor Proteins 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
238000010306 acid treatment Methods 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000007975 buffered saline Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
230000021164 cell adhesion Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
229960002424 collagenase Drugs 0.000 description 2
230000008260 defense mechanism Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000000539 dimer Substances 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
210000003989 endothelium vascular Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
102000034356 gene-regulatory proteins Human genes 0.000 description 2
108091006104 gene-regulatory proteins Proteins 0.000 description 2
230000003862 health status Effects 0.000 description 2
235000012907 honey Nutrition 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
230000000899 immune system response Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
231100000225 lethality Toxicity 0.000 description 2
238000002761 liquid phase assay Methods 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
244000005700 microbiome Species 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
239000004417 polycarbonate Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000000527 sonication Methods 0.000 description 2
241000894007 species Species 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
229930195724 β-lactose Natural products 0.000 description 2
PMTMAFAPLCGXGK-JMTMCXQRSA-N (15Z)-12-oxophyto-10,15-dienoic acid Chemical compound CC\C=C/C[C@H]1[C@@H](CCCCCCCC(O)=O)C=CC1=O PMTMAFAPLCGXGK-JMTMCXQRSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
201000001178 Bacterial Pneumonia Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241001674044 Blattodea Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
229920000832 Cutin Polymers 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000257465 Echinoidea Species 0.000 description 1
241000588921 Enterobacteriaceae Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
SPJOZZSIXXJYBT-UHFFFAOYSA-N Fenson Chemical compound C1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 SPJOZZSIXXJYBT-UHFFFAOYSA-N 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000004852 Lung Injury Diseases 0.000 description 1
102000010836 Lymphocyte Homing Receptors Human genes 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
PMTMAFAPLCGXGK-UHFFFAOYSA-N OPDA Natural products CCC=CCC1C(CCCCCCCC(O)=O)C=CC1=O PMTMAFAPLCGXGK-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101100028078 Oryza sativa subsp. japonica OPR1 gene Proteins 0.000 description 1
102000008212 P-Selectin Human genes 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000017795 Perilipin-1 Human genes 0.000 description 1
108010067162 Perilipin-1 Proteins 0.000 description 1
241000157426 Pernis Species 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
102100028927 Secretin receptor Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010069363 Traumatic lung injury Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
238000003491 array Methods 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
244000309466 calf Species 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
238000009795 derivation Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
238000002059 diagnostic imaging Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000005868 electrolysis reaction Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000001339 epidermal cell Anatomy 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
ZNOLGFHPUIJIMJ-UHFFFAOYSA-N fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000834 fixative Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
239000003292 glue Substances 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000000703 high-speed centrifugation Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000008076 immune mechanism Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
229940099472 immunoglobulin a Drugs 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000037456 inflammatory mechanism Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
239000012155 injection solvent Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000013546 insoluble monolayer Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000503 lectinlike effect Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
229940087875 leukine Drugs 0.000 description 1
230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
238000011694 lewis rat Methods 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
231100000515 lung injury Toxicity 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000000693 micelle Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000023578 negative regulation of cell adhesion Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
150000007523 nucleic acids Chemical group 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
230000032696 parturition Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
150000007965 phenolic acids Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
210000004765 promyelocyte Anatomy 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011552 rat model Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000003307 reticuloendothelial effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
235000017709 saponins Nutrition 0.000 description 1
108010038379 sargramostim Proteins 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
108700027603 secretin receptor Proteins 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000004739 secretory vesicle Anatomy 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
239000002356 single layer Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
239000002689 soil Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
231100000751 toxic capacity Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Cell Biology (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

JP4505427A 1991-01-24 1992-01-23 Ｅｌａｍ−１に対するモノクロナール抗体及びそれらの使用 Pending JPH06505253A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US64587891A	1991-01-24	1991-01-24
US645,878		1991-01-24
US73303391A	1991-07-22	1991-07-22
US733,033		1991-07-22
PCT/US1992/000577 WO1992012729A1 (en)	1991-01-24	1992-01-23	Monoclonal antibodies to elam-1 and their uses

Publications (1)

Publication Number	Publication Date
JPH06505253A true JPH06505253A (ja)	1994-06-16

Family

ID=27094802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP4505427A Pending JPH06505253A (ja)	1991-01-24	1992-01-23	Ｅｌａｍ−１に対するモノクロナール抗体及びそれらの使用

Country Status (11)

Country	Link
EP (1)	EP0568631A4 (sk)
JP (1)	JPH06505253A (sk)
AU (1)	AU1269092A (sk)
CA (1)	CA2100681A1 (sk)
IE (1)	IE920206A1 (sk)
IL (1)	IL100764A0 (sk)
NO (1)	NO932672L (sk)
NZ (1)	NZ241399A (sk)
OA (1)	OA09809A (sk)
SK (1)	SK77393A3 (sk)
WO (1)	WO1992012729A1 (sk)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2012510429A (ja) *	2008-08-25	2012-05-10	アンプリミューン、インコーポレーテッド	Ｐｄ−１アンタゴニストおよびその使用方法
WO2019078344A1 (ja) *	2017-10-20	2019-04-25	学校法人兵庫医科大学	抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
US11851486B2 (en)	2017-05-02	2023-12-26	National Center Of Neurology And Psychiatry	Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5646123A (en) *	1991-06-10	1997-07-08	Alberta Research Council	Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5660827A (en) *	1992-03-05	1997-08-26	Board Of Regents, The University Of Texas System	Antibodies that bind to endoglin
US6004555A (en) *	1992-03-05	1999-12-21	Board Of Regents, The University Of Texas System	Methods for the specific coagulation of vasculature
US5965132A (en)	1992-03-05	1999-10-12	Board Of Regents, The University Of Texas System	Methods and compositions for targeting the vasculature of solid tumors
US5877289A (en) *	1992-03-05	1999-03-02	The Scripps Research Institute	Tissue factor compositions and ligands for the specific coagulation of vasculature
CA2452130A1 (en) *	1992-03-05	1993-09-16	Francis J. Burrows	Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en)	1992-03-05	2004-06-15	Board Of Regents, The University Of Texas System	Combined methods and compositions for coagulation and tumor treatment
US6093399A (en) *	1992-03-05	2000-07-25	Board Of Regents, The University Of Texas System	Methods and compositions for the specific coagulation of vasculature
US6036955A (en) *	1992-03-05	2000-03-14	The Scripps Research Institute	Kits and methods for the specific coagulation of vasculature
US5728802A (en) *	1992-05-06	1998-03-17	Affymax Technologies N.V.	Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5648458A (en) *	1992-05-06	1997-07-15	Affymax Technologies N.V.	Peptides and compounds that bind to ELAM-1
US5643873A (en) *	1992-05-06	1997-07-01	Affymax Technologies N.V.	Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
EP0602290B1 (en) *	1992-12-04	1999-08-25	ConjuChem, Inc.	Antibody-conjugated Hepatitis B surface antigen and use thereof
US5723116A (en) *	1995-01-06	1998-03-03	University Of South Florida	Decreased mortality of severe acute pancreatitis following proximal cytokine blockade
AU6155896A (en) *	1995-06-07	1996-12-30	Cytel Corporation	Humanized antibodies to e-selectin
US6524553B2 (en)	1998-03-31	2003-02-25	Bristol-Myers Squibb Pharma Company	Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en)	1998-03-31	2003-03-25	Bristol-Myers Squibb Pharma Company	Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en)	1998-03-31	2003-04-15	Bristol-Myers Squibb Pharma Company	Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6818213B1 (en)	1998-07-13	2004-11-16	Board Of Regents, The University Of Texas System	Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
AU750414B2 (en)	1998-07-13	2002-07-18	Board Of Regents, The University Of Texas System	Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
NZ511677A (en)	1998-12-18	2003-10-31	Du Pont Pharm Co	Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en)	1998-12-18	2003-05-27	Bristol-Myers Squibb Pharma Company	Vitronectin receptor antagonist pharmaceuticals
TR200101757T2 (tr)	1998-12-18	2001-12-21	Dupont Pharmaceuticais Company	Vitronektin reseptör antagonisti farmasötikler
US6511649B1 (en)	1998-12-18	2003-01-28	Thomas D. Harris	Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en)	1998-12-18	2004-09-21	Bristol-Myers Squibb Pharma Company	Vitronectin receptor antagonist pharmaceuticals
US7030219B2 (en)	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
JP7449390B2 (ja)	2020-01-24	2024-03-13	ファイザー・インク	抗ｅ－セレクチン抗体、組成物および使用の方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE142505T1 (de) *	1988-11-14	1996-09-15	Brigham & Womens Hospital	Antikörper, spezifisch gegen elam-1 sowie deren verwendung
US5081034A (en) *	1988-11-14	1992-01-14	Brigham & Women's Hospital	Cloned genes which encode elam-1
US5272263A (en) *	1989-04-28	1993-12-21	Biogen, Inc.	DNA sequences encoding vascular cell adhesion molecules (VCAMS)

1992
- 1992-01-23 CA CA002100681A patent/CA2100681A1/en not_active Abandoned
- 1992-01-23 WO PCT/US1992/000577 patent/WO1992012729A1/en not_active Application Discontinuation
- 1992-01-23 AU AU12690/92A patent/AU1269092A/en not_active Abandoned
- 1992-01-23 SK SK773-93A patent/SK77393A3/sk unknown
- 1992-01-23 JP JP4505427A patent/JPH06505253A/ja active Pending
- 1992-01-23 EP EP92905123A patent/EP0568631A4/en not_active Withdrawn
- 1992-01-23 IE IE020692A patent/IE920206A1/en not_active Application Discontinuation
- 1992-01-24 IL IL100764A patent/IL100764A0/xx unknown
- 1992-01-24 NZ NZ241399A patent/NZ241399A/en unknown
1993
- 1993-07-22 OA OA60394A patent/OA09809A/en unknown
- 1993-07-23 NO NO93932672A patent/NO932672L/no unknown

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2012510429A (ja) *	2008-08-25	2012-05-10	アンプリミューン、インコーポレーテッド	Ｐｄ−１アンタゴニストおよびその使用方法
US11851486B2 (en)	2017-05-02	2023-12-26	National Center Of Neurology And Psychiatry	Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
WO2019078344A1 (ja) *	2017-10-20	2019-04-25	学校法人兵庫医科大学	抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
US11692037B2 (en)	2017-10-20	2023-07-04	Hyogo College Of Medicine	Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion

Also Published As

Publication number	Publication date
EP0568631A1 (en)	1993-11-10
EP0568631A4 (en)	1995-04-05
NO932672D0 (no)	1993-07-23
NO932672L (no)	1993-09-23
IE920206A1 (en)	1992-07-29
IL100764A0 (en)	1992-09-06
OA09809A (en)	1994-04-15
AU1269092A (en)	1992-08-27
CA2100681A1 (en)	1992-07-25
SK77393A3 (en)	1994-12-07
WO1992012729A1 (en)	1992-08-06
NZ241399A (en)	1994-06-27

Publication	Publication Date	Title
JPH06505253A (ja)	1994-06-16	Ｅｌａｍ−１に対するモノクロナール抗体及びそれらの使用
Russell et al.	1988	Complement receptor type 3 (CR3) binds to an Arg-Gly-Asp-containing region of the major surface glycoprotein, gp63, of Leishmania promastigotes.
Ross et al.	1987	Specificity of membrane complement receptor type three (CR3) for ß-glucans
Seon et al.	1997	Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
AU654811B2 (en)	1994-11-24	Chimeric antibodies with receptor binding ligands in place of their constant region
JP2002515235A (ja)	2002-05-28	坑アミロイド抗体を用いるアミロイドの除去方法
JP2979318B2 (ja)	1999-11-15	１７−１ａ抗原に対するモノクローナル抗体による腫瘍の免疫療法
RU2183215C2 (ru)	2002-06-10	Конъюгат для стимулирования иммунной реакции против клетки-мишени, способ лечения злокачественных опухолей у млекопитающего
JPH08505764A (ja)	1996-06-25	腫瘍血管内皮細胞に特異的に結合するモノクローナル抗体とその利用方法
JPH06501456A (ja)	1994-02-17	表面複合リンホトキシン
CN104284680A (zh)	2015-01-14	使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物
US6245334B1 (en)	2001-06-12	Method of causing selective immunosuppression using HL-60-related lectins
JP2006504773A (ja)	2006-02-09	タンパク質性化合物の毒性作用を修飾する組成物および方法
US5643740A (en)	1997-07-01	Monoclonal antibody specific for activated lymphocytes and monocytes
JPH08501535A (ja)	1996-02-20	疾患を治療するためのペプチド薬剤
Mathison et al.	2003	Modulation of neutrophil function by the tripeptide feG
Root	1990	Leukocyte adhesion proteins: their role in neutrophil function
CA2141598A1 (en)	1994-03-03	Method of inhibiting cell proliferation using apolipoprotein e
JP3030386B2 (ja)	2000-04-10	抗ガン剤
JP3236667B2 (ja)	2001-12-10	ヒト型モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ並びに抗腫瘍剤
JP2002507967A (ja)	2002-03-12	疾病治療のための抗ｃｄ４０ｌイムノトキシン
EP0486609B1 (en)	1995-03-01	Pharmaceutical product for the treatment of sepsis
Reisfeld et al.	1994	Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotheraphy
CA2182215A1 (en)	1995-08-03	Anti-inflammatory containing monoclonal antibodies having reactivity with sialyl-lewis x sugar chains originating in hemangioendothelial cell membrane
PT100568A (pt)	1993-09-30	Anticorpos monoclonais e antigeneos para o melanoma humano